Table 3.
Percentages of participants reporting low levels of knowledge/skill by profession/specialty
| Knowledge or skill | Item | Profession/Specialty | Sig.a | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Onco-logist | Rheuma-tologist | Emergency department physician | Pulmo-nologist | Patho-logist | Interventional radiologist | Clinical pharmacist | Physician assistant | Nurse practitioner | |||
| Knowledge | Safety profile of Avelumab |
70.5% (62) |
90.5% (38) |
N/A |
97.7% (42) |
N/A | N/A |
82.2% (74) |
88.1% (59) |
72.9% (62) |
0.000 |
| Safety profile of Alemtuzumab |
64.4% (56) |
85.7% (36) |
N/A |
95.2% (40) |
N/A | N/A |
80.0% (72) |
86.6% (58) |
70.9% (61) |
0.000 | |
| Safety profile of Belimumab |
79.3% (69) |
15.9% (7) |
N/A |
95.3% (41) |
N/A | N/A |
84.4% (76) |
88.1% (59) |
82.1% (69) |
0.000 | |
| Best practices for treatment of patients with lupus using immuno-oncology agents |
79.8% (63) |
6.8% (3) |
N/A | N/A | N/A |
97.4% (38) |
93.2% (82) |
83.1% (54) |
82.1% (69) |
0.000 | |
| Best practices for treatment of patients with rheumatoid arthritis or ankylosing spondylitis using immuno-oncology agents |
76.9% (60) |
6.8% (3) |
N/A | N/A | N/A |
87.5% (35) |
82% (73) |
83.1% (54) |
69.1% (58) |
0.000 | |
| Best practices for treatment of patients with psoriasis and/or psoriatic arthritis using immuno-oncology agents |
71.8% (56) |
4.6% (2) |
N/A | N/A | N/A |
89.7% (35) |
85.1% (74) |
82.8% (53) |
68.2% (58) |
0.000 | |
| Sources of information that can improve patients’ understanding of immuno-oncology agents |
64.8% (57) |
65.9% (29) |
92.7% (38) |
73.2% (30) |
N/A |
75% (33) |
75.3% (67) |
59.7% (40) |
43.9% (38) |
0.000 | |
| Sources of information that can mislead patients’ understanding of immuno-oncology agents |
67% (59) |
75% (33) |
95.1% (39) |
80.5% (33) |
N/A |
83.7% (36) |
80.9% (72) |
64.2% (43) |
56.8% (50) |
0.000 | |
| Skills | Explaining to patients the difference between immuno-oncology agents and chemotherapy |
37.5% (33) |
45.2% (19) |
82.5% (33) |
N/A | N/A |
57.1% (24) |
65.1% (56) |
33.3% (22) |
19.3% (17) |
0.000 |
| Weighing the risks and benefits of treating patients with lupus with immuno-oncology agents |
74.1% (60) |
6.8% (3) |
N/A | N/A | N/A |
94.4% (34) |
89.5% (77) |
76.6% (49) |
76.5% (62) |
0.000 | |
| Identifying viable treatment options based on pharmacodiagnostic test reports |
45.5% (20) |
N/A | N/A |
73.7% (28) |
N/A | N/A |
81% (34) |
60.5% (26) |
65.9% (29) |
0.008 | |
| Identifying markers that will characterize the progression of a specific type of cancer |
41.9% (18) |
N/A | N/A |
72.5% (29) |
46.5% (20) |
81.4% (35) |
76.2% (32) |
59.1% (26) |
54.5% (24) |
0.000 | |
N/A = Question was not asked to this profession/specialty sub-group
aSignificance across all profession/specialty sub-groups determined by two-sided Pearson’s chi-square tests